In eosinophilic esophagitis, budesonide orodispersible tablets maintained remission at 48 wk

Ann Intern Med. 2021 Apr;174(4):JC44. doi: 10.7326/ACPJ202104200-044. Epub 2021 Apr 6.

Abstract

Straumann A, Lucendo AJ, Miehlke S, et al. Budesonide orodispersible tablets maintain remission in a randomized, placebo-controlled trial of patients with eosinophilic esophagitis. Gastroenterology. 2020;159:1672-85. 32721437.

Keywords: Budesonide; Eosinophilic esophagitis; Glucocorticoids.

Publication types

  • Comment

MeSH terms

  • Budesonide*
  • Eosinophilic Esophagitis* / drug therapy
  • Glucocorticoids
  • Humans
  • Tablets
  • Treatment Outcome

Substances

  • Glucocorticoids
  • Tablets
  • Budesonide